Retinal tissue derived from human pluripotent stem cells for vision restoration
Award amount
$2,230,814Program and phase
SBIR · Phase IAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- BioTime, Inc.
- Proposal award date
- 2017-09-30
- Contract end date
- 2020-05-31
- UEI
- JB7RMLG8U699
- Solicitation number
- PA18-591
- Topic code
- NEI
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Stroke
- Cell Targeting Peptides for Isolating Patient Specific Stem Cells
- SBIR Topic 314- High Content Screening of 3D Cultured Cancer Cells
- Biodegradable, hyaluronic acid-based microcarriers for mesenchymal stem cell prop
- Resuscitating Blood-Substituted Hypothermic Dogs
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Humidifeye Plug for Dry Eye Disease
- A Novel Therapeutic to Promote Corneal Repair
- Drug Screening Platform in the Light-Responsive Human Eye
- RetiVue EntireEye - A Handheld, High-Resolution, Non-Contact, One Image, Widefield Retinal Screening Camera for Premature and Healthy Newborn Babies
- The iD2: A Smart Eye Drop Cap Monitor for Eye Drop Adherence
Research funding history
6 SBIR/STTR records share this UEI (2004–2018). Reported award amounts total $3,762,961. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services